Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but
despite 20 years of intensive use, it remains a drug with a number of still obscure …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

PURPOSE Understanding the immunobiology of the 15% to 30% of patients with follicular
lymphoma (FL) who experience progression of disease within 24 months (POD24) remains …

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit
follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) …

Clinical features and outcomes of FL patients in Chinese population are limited, thus
promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled …

Anti‐CD20 antibody in combination with chemotherapy extends overall survival (OS) in
untreated advanced‐stage follicular lymphoma (FL), yet the optimal associated therapy is …

Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day
treatments, long remissions are often achieved both in the front-line and relapsed setting …

Objective Active surveillance (AS) represents a fundamental shift in managing select cancer
patients that initiates treatment only upon disease progression to avoid overtreatment. Given …

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and most
common indolent non-Hodgkin lymphoma. Lower socioeconomic status is associated with …

Background The data about the clinical features and outcomes of Chinese patients with
follicular lymphoma (FL) are limited. Here, we conducted a retrospective study to explore the …